KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Receivables: 2014-2025

Historic Receivables for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Sep 2025 value amounting to $30.7 million.

  • Aurinia Pharmaceuticals' Receivables fell 15.81% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.7 million, marking a year-over-year increase of 28.42%. This contributed to the annual value of $36.5 million for FY2024, which is 51.70% up from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Receivables is $30.7 million, which was down 23.35% from $40.1 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Receivables ranged from a high of $41.8 million in Q3 2022 and a low of $1.2 million during Q1 2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Receivables had a median value of $30.7 million in 2025 and averaged $30.8 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Receivables spiked by 1,600.08% in 2022 and then decreased by 15.81% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Receivables stood at $15.4 million in 2021, then decreased by 12.42% to $13.5 million in 2022, then soared by 78.44% to $24.1 million in 2023, then spiked by 51.70% to $36.5 million in 2024, then fell by 15.81% to $30.7 million in 2025.
  • Its last three reported values are $30.7 million in Q3 2025, $40.1 million for Q2 2025, and $40.4 million during Q1 2025.